Drug intelligence / Profile preview

1G3

Development stage: Preclinical
Lead developer: Biogen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intraperitoneal

Overview

1G3 is a monoclonal antibody specifically designed to target and block the neonatal Fc receptor (FcRn) in rats. FcRn is a key homeostatic regulator of immunoglobulin G (IgG), protecting it from lysosomal degradation and extending its serum half-life. By binding to and blocking FcRn, 1G3 promotes the catabolism of endogenous IgG, including pathogenic autoantibodies. This mechanism of action has been utilized in preclinical research to demonstrate the potential for FcRn blockade in treating antibody-mediated autoimmune diseases, such as myasthenia gravis, where reducing the concentration of pathogenic antibodies can ameliorate disease symptoms.

Other names: anti-rat FcRn mAb 1G3anti-FcRn monoclonal antibody 1G3

Targets

FCGRT (Neonatal crystallizable fragment receptor)

Beyond the preview

Go deeper on 1G3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1G3.

Explore the full profile